Chapter 33 : Antifungal Drug Interactions

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Zoom in

Antifungal Drug Interactions, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815523/9781555814380_Chap33-1.gif /docserver/preview/fulltext/10.1128/9781555815523/9781555814380_Chap33-2.gif


The risk of an adverse effect with a drug interaction is further increased in patients with advanced age, malnutrition, malabsorption, chronic illness, hepatic or renal dysfunction, polypharmacy, or concomitant use of drugs with a narrow therapeutic index or in patients whose care is provided by multiple specialists or prescribers. As many or all of these risk factors are present in the patient populations predisposed to invasive fungal infections, drug interactions should be anticipated in any patient receiving systemic antifungal therapy for invasive aspergillosis. This chapter focuses on mechanisms and clinical implications of pharmacokinetic drug-drug interactions in the patient with aspergillosis. The density of P-gp expression in the gastrointestinal tract exhibits wide intra- and interpatient variability that is affected by diet, underlying disease, drug therapy, and genetics. Some chemotherapy agents and immunosuppressants used in solid organ or hematopoetic stem cell transplantation are extensively cleared through CYP3A4 biotransformation. Management of these interactions focuses on preventative measures to limit the severity of the reaction and careful monitoring and supplementation of electrolyte deficiencies. Patients with invasive aspergillosis have multiple risk factors for potentially harmful drug interactions. Although some drug interactions may be trivial or have minor effects, interactions that enhance the metabolism of antifungals used to treat infection, interactions that affect drugs with a narrow therapeutic index (i.e., immunosuppressants, chemotherapy, antiretrovirals), and interactions that increase cardiac QT prolongation should always be considered important and managed in a proactive fashion.

Citation: Lewis R. 2009. Antifungal Drug Interactions, p 445-456. In Latgé J, Steinbach W (ed), and Aspergillosis. ASM Press, Washington, DC. doi: 10.1128/9781555815523.ch33

Key Concept Ranking

Fungal Infections
Antifungal Agents
Antifungal Drugs
ATP-Binding Cassette Superfamily
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of Figure 1.
Figure 1.

Mechanisms of pharmacokinetic variability and drug-drug interactions in the gastrointestinal and hepatobiliary tracts. Most antifungal agents are absorbed by passive diffusion. Intestinal enterocytes can efflux drug out of the cell by action of the P-gp pump. Mixed function oxidases (primarily CYP3A4/3A5) oxidize the drug before it reaches the portal circulation. The overlapping substrate specificity of P-gp and CYP3A4/5 represents a complementary barrier against drug absorption that serves as a possible source for drug interactions with orally absorbed antifungal agents.

Citation: Lewis R. 2009. Antifungal Drug Interactions, p 445-456. In Latgé J, Steinbach W (ed), and Aspergillosis. ASM Press, Washington, DC. doi: 10.1128/9781555815523.ch33
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2.
Figure 2.

TdP risk stratification schedules for antimicrobial agents. *, antimicrobial agent that is new to the market or still investigational and has minimal to no postmarketing data; based on additional data, the drug may be recategorized in a higher or lower schedule. I, rapid component of the delayed rectifier potassium current. Adapted from Owens (2004) with the permission of the publisher.

Citation: Lewis R. 2009. Antifungal Drug Interactions, p 445-456. In Latgé J, Steinbach W (ed), and Aspergillosis. ASM Press, Washington, DC. doi: 10.1128/9781555815523.ch33
Permissions and Reprints Request Permissions
Download as Powerpoint


1. Baildon, R.,, T. Patterson,, H. W. Boucher,, R. Tiernan, and, J. H. Powers. 2001. NDA 21-266, Vfend(tm) (voriconazole) tablets, and NDA 21-267, Vfend(tm) I.V. (voriconazole) for infusion. [Slide, October 4, 2001.] (Online.) http://www.fda.gov/ohrms/dockets/ac/01/slides/3792s2.htm
2. Barrons, R. 2004. Evaluation of personal digital assistant software for drug interactions. Am. J. Health Syst. Pharm. 61: 380385.
3. Billaud, E. M.,, R. Guillemain,, F. Tacco, and, P. Chevalier. 1998. Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients. Br. J. Clin. Pharmacol. 46: 271272.
4. Bonay, M.,, A. P. Jonville-Bera,, P. Diot,, E. Lemarie,, M. Lavandier, and, E. Autret. 1993. Possible interaction between phenobarbital, carbamazepine and itraconazole. Drug Saf. 9: 309311.
5. Branch, R. A. 1988. Prevention of amphotericin B-induced renal impairment: a review on the use of sodium supplementation. Arch. Intern. Med. 148:23892394.
6. Burget, D. W.,, S. G. Chiverton, and, R. H. Hunt. 1990. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 99:345351.
7. Capone, D.,, A. Gentile,, P. Imperatore,, G. Palmiero, and, V. Basile. 1999. Effects of itraconazole on tacrolimus blood concentrations in a renal transplant recipient. Ann. Pharmacother. 33:11241125.
8. Capone, D.,, A. Gentile,, P. Vajro,, P. Stanziale,, P. Imperatore,, C. De Silva,, T. Pellegrino, and, V. Basile. 1998. Therapeutic monitoring of tacrolimus in pediatric and adult transplanted patients. J. Che-mother. 10:176178.
9. Cavuto, N. J.,, R. L. Woosley, and, M. Sale. 1996. Pharmacies and prevention of potentially fatal drug interactions. JAMA 275: 10861087.
10. Chiang, C. E. 2004. Congenital and acquired long QT syndrome. Current concepts and management. Cardiol. Rev. 12:222234.
11. Chiang, C. E., and, D. M. Roden. 2000. The long QT syndromes: genetic basis and clinical implications. J. Am. Coll. Cardiol. 36: 112.
12. Chung, D. K., and, M. G. Koenig. 1971. Reversible cardiac enlargement during treatment with amphotericin B and hydrocortisone. Report of three cases. Am. Rev. Respir. Dis. 103:831841.
13. Clauson, K. A.,, H. H. Polen, and, W. A. Marsh. 2007. Clinical decision support tools: performance of personal digital assistant versus online drug information databases. Pharmacotherapy 27: 16511658.
14. Courtney, R.,, S. Pai,, M. Laughlin,, J. Lim, and, V. Batra. 2003. Phar-macokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob. Agents Chemother. 47:27882795.
15. Courtney, R.,, A. Sansone,, W. Smith,, T. Marbury,, P. Statkevich,, M. Martinho,, M. Laughlin, and, S. Swan. 2005. Posaconazole phar-macokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J. Clin. Pharmacol. 45:185192.
16. Courtney, R.,, D. Wexler,, E. Radwanski,, J. Lim, and, M. Laughlin. 2004. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br. J. Clin. Pharmacol. 57:218222.
17. Depont, F.,, F. Vargas,, H. Dutronc,, E. Giauque,, J. M. Ragnaud,, T. Galperine,, A. Abouelfath,, R. Valentino,, M. Dupon,, G. Hebert, and, N. Moore. 2007. Drug-drug interactions with systemic antifungals in clinical practice. Pharmacoepidemiol. Drug Saf. 16:12271233.
18. Ducharme, M. P.,, R. L. Slaughter,, L. H. Warbasse,, P. H. Chandra-sekar,, V. Van de Velde,, G. Mannens, and, D. J. Edwards. 1995. Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. Clin. Pharmacol. Ther. 58: 617624.
19. Eiden, C.,, H. Peyriere,, R. Tichit,, M. Cociglio,, P. Amedro,, J. P. Blayac,, G. Margueritte, and, D. Hillaire-Buys. 2007. Inherited long QT syndrome revealed by antifungals drug-drug interaction. J. Clin. Pharm. Ther. 32:321324.
20. Gaddis, G. M.,, T. R. Holt, and, M. Woods. 2002. Drug interactions in at-risk emergency department patients. Acad. Emerg. Med. 9: 11621167.
21. Gallicano, K., and, G. L. Drusano. 2005. Introduction to drug interactions, p. 112. In S. Piscitelli and, K. Rodvold (ed.), Drug Interactions in Infectious Diseases, 2nd ed. Humana Press, Totowa, NJ.
22. Glasmacher, A.,, C. Hahn,, E. Molitor,, G. Marklein,, T. Sauerbruch, and, I. G. H. Schmidt-Wolf. 1999. Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coatedpellet capsules. Mycoses 42:591600.
23. Goodwin, M. L., and, R. H. Drew. 2008. Antifungal serum concentration monitoring: an update. J. Antimicrob. Chemother. 61: 1725.
24. Grillot, R., and, B. Lebeau. 2005 Systemic antifungal agents, p. 12601287. In A. Bryskier (ed.), Antimicrobial Agents: Antibacterials and Antifungals. ASM Press, Washington, DC.
25. Groll, A., and, T. J. Walsh. 1998. Pharmacology of antifungal compounds. Adv. Pharmacol. 44: 343500.
26. Gubbins, P. O.,, S. A. McConnell, and, J. R. Amsden. 2005 Antifungal agents, p. 289338. In S. Piscitelli and, K. Rodvold (ed.), Drug Interactions in Infectious Diseases, 2nd ed. Humana Press, Totowa, NJ.
27. Hall, S. D.,, K. E. Thummel,, P. B. Watkins,, K. S. Lown,, L. Z. Benet,, M. F. Paine,, R. R. Mayo,, D. K. Turgeon,, D. G. Bailey,, R. J. Fon-tana, and, S. A. Wrighton. 1999. Molecular and physical mechanisms of first-pass extraction. Drug Metab. Dispos. 27:161166.
28. Hazlet, T. K.,, T. A. Lee,, P. D. Hansten, and, J. R. Horn. 2001. Performance of community pharmacy drug interaction software. J. Am. Pharm. Assoc. 41:200204.
29. Heidemann, H. T.,, J. F. Gerkens,, W. A. Spickard,, E. K. Jackson, and, R. A. Branch. 1983. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am. J. Med. 75:476481.
30. Ikeda, Y.,, K. Umemura,, K. Kondo,, K. Sekiguchi,, S. Miyoshi, and, M. Nakashima. 2004. Pharmacokinetics of voriconazole and cyto-chrome P450 2C19 genetic status. Clin. Pharmacol. Ther. 75: 587588.
31. Kanda, Y.,, M. Kami,, T. Matsuyama,, K. Mitani,, S. Chiba,, Y. Yazaki, and, H. Hirai. 1998. Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. Hematol. Oncol. 16:3337.
32. Kashuba, D. M., and, J. S. Bertino. 2005. Mechanisms of drug interactions I, p. 1339. In S. Piscitelli and, K. Rodvold (ed.), Drug Interactions in Infectious Diseases, 2nd ed. Humana Press, Totowa, NJ.
33. Kim, R. B. 2003. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur. J. Clin. Investig. 33:(Suppl. 2):15.
34. Krishna, G.,, A. Parsons,, B. Kantesaria, and, T. Mant. 2007. Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men. Curr. Med. Res. Opin. 23: 545552.
35. Lange, D.,, J. H. Pavao,, J. Wu, and, M. Klausner. 1997. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J. Clin. Pharmacol. 37:535540.
36. Lewis, R. E. 2006. Managing drug interactions in the patient with aspergillosis. Med. Mycol. 44:(Suppl.):349356.
37. Lim, S. G.,, A. M. Sawyerr,, M. Hudson,, J. Sercombe, and, P. E. Pounder. 1993. Short report: the absorption of fluconazole and itra-conazole under conditions of low intragastric acidity. Aliment. Pharmacol. Ther. 7: 317321.
38. Lown, K. S.,, J. C. Kolars,, K. E. Thummel,, J. L. Barnett,, K. L. Kunze,, S. Wrighton, and, P. B. Watkins. 1994. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab. Dispos. 22: 947955.
39. Marr, K. A.,, W. Leisenring,, F. Crippa,, J. T. Slattery,, L. Corey,, M. Boeckh, and, G. B. McDonald. 2004. Cyclophosphamide metabolism is affected by azole antifungals. Blood 103:15571559.
40. Marty, F. M.,, C. M. Lowry,, C. S. Cutler,, B. J. Campbell,, K. Fiumara,, L. R. Baden, and, J. H. Antin. 2006. Voriconazole and sirolimus co-administration after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 12:552559.
41. Meletiadis, J.,, S. Chanock, and, T. J. Walsh. 2006. Human pharma-cogenomic variations and their implications for antifungal efficacy. Clin. Microbiol. Rev. 19:763787.
42. Nicolau, D. P.,, H. M. Crowe,, C. H. Nightingale, and, R. Quintiliani. 1995. Rifampin-fluconazole interaction in critically ill patients. Ann. Pharmacother. 29:994996.
43. Owens, R. C., Jr. 2004. QT prolongation with antimicrobial agents: understanding the significance. Drugs 64:10911124.
44. Pascual, A.,, T. Calandra,, S. Bolay,, T. Buclin,, J. Bille, and, O. Mar-chetti. 2007. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves safety and efficacy outcomes. Clin. Infect. Dis. 46:201211.
45. Penzak, S. R. 2005 Mechanisms of drug interactions II, p. 4182. In S. Piscitelli and, K. Rodvold (ed.), Drug Interactions in Infectious Diseases, 2nd ed. Humana Press, Totowa, NJ.
46. Perkins, N. A.,, J. E. Murphy,, D. C. Malone, and, E. P. Armstrong. 2006. Performance of drug-drug interaction software for personal digital assistants. Ann. Pharmacother. 40:850855.
47. Pfizer, Inc. 2001. New drug application 21-266, Vfend (voriconazole) tablets, and new drug application 21-267, Vfend I.V. (voriconazole) for infusion. Accessed 30 December 2007. http://www.fda.gov/cder/foi/nda/2002/21-266 21-267Vfend.htm.
48. Poirier, J. M., and, G. Cheymol. 1998. Optimisation of itraconazole therapy using target drug concentrations. Clin. Pharmacokinet. 35: 461473.
49. Riechelmann, R. P. 2007. Drug combinations with the potential to interact among cancer patients. Support. Care Cancer 15: 11131114.
50. Riechelmann, R. P., and, E. D. Saad. 2006. A systematic review on drug interactions in oncology. Cancer Investig. 24:704712.
51. Romero, A. J.,, P. Le Pogamp,, L. G. Nilsson, and, N. Wood. 2002. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin. Pharmacol. Ther. 71:226234.
52. Saad, A. H.,, D. D. DePestel, and, P. L. Carver. 2006. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Phar-macotherapy 26:17301744.
53. Sandhu, P.,, W. Lee,, X. Xu,, B. F. Leake,, M. Yamazaki,, J. A. Stone,, J. H. Lin,, P. G. Pearson, and, R. B. Kim. 2005. Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab. Dispos. 33: 676682.
54. Sansone-Parsons, A.,, G. Krishna,, M. Martinho,, B. Kantesaria,, S. Ge-lone, and, T. G. Mant. 2007a. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 27:825834.
55. Sansone-Parsons, A.,, G. Krishna,, J. Simon,, P. Soni,, B. Kantesaria,, J. Herron, and, R. Stoltz. 2007b. Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob. Agents Chemother. 51:495502.
56. Sanz-Rodriguez, C.,, M. Lopez-Duarte,, M. Jurado,, J. Lopez,, R. Ar-ranz,, J. M. Cisneros,, M. L. Martino,, P. J. Garcia-Sanchez,, P. Morales,, T. Olive,, M. Rovira, and, C. Solano. 2004. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant. 34:1320.
57. Schaeffeler, E.,, M. Eichelbaum,, U. Brinkmann,, A. Penger,, S. Asante-Poku,, U. M. Zanger, and, M. Schwab. 2001. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 358:383384.
58. Schering-Plough, Inc. 2006. New drug application 022003, Noxafil (posaconazole) oral suspension. Accessed 30 December 2007. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist.
59. Schering-Plough, Inc. 26 February 1998. Antifungal composition with enhanced bioavailability. Patent WO/1998/007429. http://wipo.int/pctdb/en.
60. Shon, J. H.,, Y. R. Yoon,, W. S. Hong,, P. M. Nguyen,, S. S. Lee,, Y. G. Choi,, I. J. Cha, and, J. G. Shin. 2005. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Clin. Pharmacol. Ther. 78: 191201.
61. Smith, G.,, M. J. Stubbins,, L. W. Harries, and, C. R. Wolf. 1998. Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica 28: 11291165.
62. Smith, J.,, N. Safdar,, V. Knasinski,, W. Simmons,, S. M. Bhavnani,, P. G. Ambrose, and, D. Andes. 2006. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother. 50: 15701572.
63. Stevens, D. A. 1999. Itraconazole in cyclodextrin solution. Pharma-cotherapy 19: 603611.
64. Summers, K. K.,, T. C. Hardin,, S. J. Gore, and, J. R. Graybill. 1997. Therapeutic drug monitoring of systemic antifungal therapy. J. Antimicrob. Chemother. 40: 753764.
65. Tan, K.,, N. Brayshaw,, K. Tomaszewski,, P. Troke, and, N. Wood. 2006. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J. Clin. Pharmacol. 46: 235243.
66. Van de Velde, V. J.,, A. P. Van Peer,, J. J. Heykants,, R. J. Woesten-borghs,, P. Van Rooy,, K. L. De Beule, and, G. F. Cauwenbergh. 1996. Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole. Phar-macotherapy 16:424428.
67. Walsh, T. J.,, I. I. Raad,, T. F. Patterson,, P. Chandrasekar,, G. R. Don-owitz,, R. Graybill,, R. E. Greene,, R. Hachem,, S. Hadley,, R. Her-brecht,, A. Langston,, A. Louie,, P. Ribaud,, B. H. Segal,, D. A. Stevens,, J. A. van Burik,, C. S. White,, G. Corcoran,, J. Gogate,, G. Krishna,, L. Pedicone,, C. Hardalo, and, J. R. Perfect. 2007. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 44: 212.
68. Wang, E. J.,, K. Lew,, C. N. Casciano,, R. P. Clement, and, W. W. Johnson. 2002. Interaction of common azole antifungals with P gly-coprotein. Antimicrob. Agents Chemother. 46:160165.
69. Wiederhold, N. P., and, J. S. Lewis II. 2007. The echinocandin mica-fungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin. Pharmacother. 8:11551166.
70. Wingard, J. R.,, P. Kubilis,, L. Lee,, G. Yee,, M. White,, L. Walshe,, R. Bowden,, E. Anaissie,, J. Hiemenz, and, J. Lister. 1999. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin. Infect. Dis. 29: 14021407.
71. Wong, R.,, G. Z. Beguelin,, M. de Lima,, S. A. Giralt,, C. Hosing,, C. Ippoliti,, A. D. Forman,, A. J. Kumar,, R. D. Champlin, and, D. Cour-iel. 2003. Tacrolimus-associated posterior reversible encephalopa-thy syndrome after allogeneic haematopoietic stem cell transplantation. Br. J. Haematol. 122:128134.
72. Wood, N.,, K. Tan,, R. Allan,, A. Fielding, and, D. Nichols. 2001. Effect of voriconazole on the pharmacokinetics of tacrolimus. Abstr.41st Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL. American Society for Microbiology, Washington, DC.
73. Yu, D. T.,, J. F. Peterson,, D. L. Seger,, W. C. Gerth, and, D. W. Bates. 2005. Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions. Pharmacoepi-demiol. Drug Saf. 14: 755767.


Generic image for table
Table 1.

Antifungal characteristics that predispose to potential adverse drug interactions

Citation: Lewis R. 2009. Antifungal Drug Interactions, p 445-456. In Latgé J, Steinbach W (ed), and Aspergillosis. ASM Press, Washington, DC. doi: 10.1128/9781555815523.ch33
Generic image for table
Table 2.

Comparative CYP P450 interaction profiles of the triazole antifungals

Citation: Lewis R. 2009. Antifungal Drug Interactions, p 445-456. In Latgé J, Steinbach W (ed), and Aspergillosis. ASM Press, Washington, DC. doi: 10.1128/9781555815523.ch33
Generic image for table
Table 3.

Summary of common drug interactions affecting hepatic biotransformation and clearance in patients with aspergillosis

Citation: Lewis R. 2009. Antifungal Drug Interactions, p 445-456. In Latgé J, Steinbach W (ed), and Aspergillosis. ASM Press, Washington, DC. doi: 10.1128/9781555815523.ch33
Generic image for table
Table 4.

Recommendations for therapeutic drug monitoring of antifungal therapy in patients with aspergillosis

Citation: Lewis R. 2009. Antifungal Drug Interactions, p 445-456. In Latgé J, Steinbach W (ed), and Aspergillosis. ASM Press, Washington, DC. doi: 10.1128/9781555815523.ch33

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error